Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Rebecca Olin, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Rebecca Olin, MD
Professor, Medicine, School of Medicine. Authored (or co-authored) 79 research publications. Research interests: acute myeloid leukemia (AML) · acute lymphoblastic leukemia (ALL) · acute promyelocytic leukemia (APL) · myelodysplastic syndrome (MDS) · hematopoietic stem cell transplantation · myeloproliferative neoplasms (MPN) · aplastic anemia · lymphoma · multiple myeloma
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Beat AML, LLC
- Links
- more information about this study: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
- ID
- NCT03013998
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 2000 study participants
- Last Updated